Avant Technologies and JV Partner, Ainnova, Strategically Align with Apollo Hospitals to Advance AI in Healthcare
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have announced a strategic collaboration with Apollo Hospitals to advance AI in healthcare. Ainnova has secured exclusive licenses for AI algorithms validated with over 2.3 million data points for their Vision AI platform.
The platform enables early detection of various conditions including cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Following Avant and Ainnova's recent global development deal through their joint venture AAC, the AI diagnostics will be launched commercially across the Americas in the coming weeks.
The partnership has already received regulatory approval from ANVISA for expansion into Brazil's 200-million-person market. The collaboration aims to enhance chronic disease management by facilitating early referrals from primary care providers and community health services to specialists.
Avant Technologies (OTCQB:AVAI) e il suo partner Ainnova Tech hanno annunciato una collaborazione strategica con Apollo Hospitals per promuovere l'IA nella sanità. Ainnova ha ottenuto licenze esclusive per algoritmi di IA convalidati con oltre 2,3 milioni di punti dati per la loro piattaforma Vision AI.
La piattaforma consente la diagnosi precoce di varie condizioni, tra cui malattie cardiovascolari, malattie renali croniche, fibrosi epatica, diabete di tipo 2 e anomalie polmonari. Dopo l'accordo di sviluppo globale recentemente concluso tra Avant e Ainnova attraverso la loro joint venture AAC, i diagnostici basati sull'IA saranno lanciati commercialmente nelle Americhe nelle prossime settimane.
La partnership ha già ricevuto l'approvazione normativa da ANVISA per l'espansione nel mercato brasiliano di 200 milioni di persone. La collaborazione mira a migliorare la gestione delle malattie croniche facilitando i rinvii precoci dai fornitori di cure primarie e dai servizi sanitari comunitari agli specialisti.
Avant Technologies (OTCQB:AVAI) y su socio Ainnova Tech han anunciado una colaboración estratégica con Apollo Hospitals para avanzar en la IA en la atención médica. Ainnova ha asegurado licencias exclusivas para algoritmos de IA validados con más de 2,3 millones de puntos de datos para su plataforma Vision AI.
La plataforma permite la detección temprana de diversas condiciones, incluyendo enfermedades cardiovasculares, enfermedades renales crónicas, fibrosis hepática, diabetes tipo 2 y anomalías pulmonares. Tras el reciente acuerdo de desarrollo global de Avant y Ainnova a través de su empresa conjunta AAC, los diagnósticos de IA se lanzarán comercialmente en las Américas en las próximas semanas.
La asociación ya ha recibido la aprobación regulatoria de ANVISA para la expansión en el mercado brasileño de 200 millones de personas. La colaboración tiene como objetivo mejorar la gestión de enfermedades crónicas facilitando los remisiones tempranas de los proveedores de atención primaria y los servicios de salud comunitarios a los especialistas.
Avant Technologies (OTCQB:AVAI)와 그 파트너 Ainnova Tech는 Apollo Hospitals와 협력하여 의료 분야의 AI 발전을 위한 전략적 협업을 발표했습니다. Ainnova는 Vision AI 플랫폼을 위해 230만 개 이상의 데이터 포인트로 검증된 AI 알고리즘에 대한 독점 라이센스를 확보했습니다.
이 플랫폼은 심혈관 질환, 만성 신장 질환, 간 섬유증, 제2형 당뇨병 및 폐 이상을 포함한 다양한 질병의 조기 발견을 가능하게 합니다. Avant와 Ainnova가 공동 벤처 AAC를 통해 최근 체결한 글로벌 개발 계약에 따라, AI 진단은 향후 몇 주 내에 아메리카 전역에서 상업적으로 출시될 예정입니다.
이 파트너십은 이미 2억 인구의 브라질 시장으로의 확장을 위해 ANVISA의 규제 승인을 받았습니다. 이 협력은 1차 진료 제공자와 지역 사회 건강 서비스로부터 전문의에게 조기 의뢰를 촉진하여 만성 질환 관리를 향상시키는 것을 목표로 하고 있습니다.
Avant Technologies (OTCQB:AVAI) et son partenaire Ainnova Tech ont annoncé une collaboration stratégique avec Apollo Hospitals pour faire avancer l'IA dans le secteur de la santé. Ainnova a obtenu des licences exclusives pour des algorithmes d'IA validés avec plus de 2,3 millions de points de données pour leur plateforme Vision AI.
La plateforme permet la détection précoce de diverses conditions, y compris les maladies cardiovasculaires, les maladies rénales chroniques, la fibrose hépatique, le diabète de type 2 et les anomalies pulmonaires. Suite à l'accord de développement mondial récent entre Avant et Ainnova par le biais de leur coentreprise AAC, les diagnostics basés sur l'IA seront commercialement lancés dans les Amériques dans les semaines à venir.
Le partenariat a déjà reçu l'approbation réglementaire de l'ANVISA pour une expansion sur le marché brésilien de 200 millions de personnes. La collaboration vise à améliorer la gestion des maladies chroniques en facilitant les références précoces des prestataires de soins primaires et des services de santé communautaires vers des spécialistes.
Avant Technologies (OTCQB:AVAI) und sein Partner Ainnova Tech haben eine strategische Zusammenarbeit mit Apollo Hospitals angekündigt, um KI im Gesundheitswesen voranzutreiben. Ainnova hat exklusive Lizenzen für KI-Algorithmen gesichert, die mit über 2,3 Millionen Datenpunkten für ihre Vision AI-Plattform validiert wurden.
Die Plattform ermöglicht die frühzeitige Erkennung verschiedener Erkrankungen, darunter Herz-Kreislauf-Erkrankungen, chronische Nierenerkrankungen, Leberfibrose, Typ-2-Diabetes und Lungenanomalien. Nach dem kürzlichen globalen Entwicklungsvertrag von Avant und Ainnova über ihr Joint Venture AAC werden die KI-Diagnosen in den kommenden Wochen kommerziell in Amerika eingeführt.
Die Partnerschaft hat bereits die regulatorische Genehmigung von ANVISA für die Expansion in den brasilianischen Markt mit 200 Millionen Menschen erhalten. Die Zusammenarbeit zielt darauf ab, das Management chronischer Erkrankungen zu verbessern, indem frühzeitige Überweisungen von Hausärzten und Gemeinschaftsgesundheitsdiensten an Fachärzte erleichtert werden.
- Secured exclusive license for AI algorithms validated with 2.3M+ data points
- Obtained ANVISA regulatory approval for Brazilian market entry
- Imminent commercial launch across Americas
- Partnership with major healthcare provider Apollo Hospitals expands market reach
- None.
LAS VEGAS, NV / ACCESS Newswire / March 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Apollo Hospitals (Apollo) and Ainnova have officially established a strategic collaboration that marks a significant step forward in the integration of artificial intelligence into disease detection and prediction.
As part of this alliance, Ainnova has secured an exclusive license for several advanced AI algorithms, which have been rigorously validated with over 2.3 million data points and now form an integral part of Ainnova's Vision AI platform. These cutting-edge solutions enable the early and precise detection of conditions, such as cardiovascular disease (CVD), chronic kidney disease (CKD), liver fibrosis, type 2 Diabetes, and lung abnormalities in CT scans and X-rays, including lung cancer.
Last month, Avant and Ainnova signed a global development and licensing deal for Ai-Nova Acquisition Corp. (AAC), the joint venture formed by both companies. Given AAC's territory now includes a global license to develop and market Ainnova's technology portfolio, this partnership with Apollo strengthens the joint venture's efforts to advance AI in Healthcare using Ainnova's Vision AI platform and its proprietary versatile retinal camera technology.
This week, most of these AI-driven diagnostics will be available exclusively on the Vision AI platform across the Americas, where the first commercial pilot programs are set to launch in the coming weeks.
Notably, Brazil is already included in the expansion roadmap, as the partnership has successfully met the regulatory requirements set by ANVISA (Brazilian Health Regulatory Agency). This milestone paves the way for commercialization in a country with over 200-million people.
The integration of these AI-powered solutions aligns with efforts to enhance chronic disease management by adding substantial value to patient care. By providing a comprehensive preventive health assessment, these tools aim to facilitate early referrals from primary care providers or community health services, such as pharmacies, to specialized medical professionals.
Apollo Hospitals is one of the largest and most renowned private healthcare networks in Asia, playing a leading role in transforming healthcare in India and across Southeast Asia. With a robust presence that includes hospitals, clinics, pharmacies, and diagnostic centers in the region and beyond, Apollo remains at the forefront of medical innovation.
With this alliance, Apollo reaffirms its commitment to advancing global healthcare by leveraging AI-powered solutions. Partnering with Ainnova in the Americas underscores its dedication to driving innovation, improving patient outcomes, and expanding access to state-of-the-art medical technologies. Together, the two organizations will continue to develop and deploy AI-driven healthcare solutions with additional innovations set to be introduced in the near future.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Apollo Hospitals
Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is India's largest integrated healthcare platform with over 10,000 beds across 73 hospitals, over 6000 pharmacies and over 200 clinics and diagnostic centers, as well as 150 telemedicine centers. It is the world's leading cardiac center with over 200,000 surgeries and the world's largest private cancer care provider. Apollo continues to invest in research to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have the best available care in the world. Apollo's 100,000 family members are dedicated to bringing you the best care and leaving the world better than we found it.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
FAQ
What diseases can Avant Technologies (AVAI) and Ainnova's AI platform detect?
When will AVAI's AI diagnostic tools launch in the Americas?
How many data points were used to validate AVAI's AI algorithms?
Has AVAI received regulatory approval for the Brazilian market?
